IMR Press / EJGO / Volume 34 / Issue 6 / pii/1630906506389-1998990417

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Attitudes and practices of Korean gynecologists towards hormone replacement therapyin endometrial cancer survivors
Show Less
1 Department of Obstetrics and Gynecology, St. Vincent’s Hospital, School of Medicine, The Catholic University of Korea, Suwon
2 East-West Medical Research Institutes, Kyung Hee University, Seoul
3 Department of Obstetrics and Gynecology, KonKuk Univeristy Medical Center, Seoul (Korea)
Eur. J. Gynaecol. Oncol. 2013, 34(6), 513–517;
Published: 10 December 2013

Purpose: To investigate the attitudes of Korean gynecologists towards prescribing hormone replacement therapy (HRT) after treatment for endometrial cancer. Materials and Methods: A questionnaire, addressing attitudes towards HRT and treatment strategies for patients previously treated for endometrial cancer, was distributed to 163 Korean gynecologists. Results: Of the 163 gynecologists that were sent this questionnaire, 98 (60.1%) responded. Among the respondents, 81 (82.7%) had previously prescribed HRT to patients with endometrial cancer. Of the latter, 75 (92.6%) had prescribed HRT to patients with Stage I, and more than half to patients with Stage II, endometrial cancer. Of the respondents who had prescribed HRT, 33 (40.7%) did so without regard for cancer-cell type and 33 (40.7%) began patients on HRT more than two years after endometrial cancer treatment. Tibolone was the most commonly prescribed drug (61.9%). The most common reason not to prescribe HRT was fear of cancer recurrence (38.1%). Conclusion: Most of the Korean gynecologists surveyed had experience prescribing HRT to endometrial cancer patients. Although HRT is not actively recommended, HRT given post-therapy to endometrial cancer patients is considered acceptable.
Endometrial cancer
Hormone replacement therapy
Back to top